Recombinant Antibodies
Tips and technical resources to kickstart your experiments and keep them moving forward, including concentration calculations, centrifuges, sample management, and more.
Recombinant antibodies are antibody proteins produced using recombinant DNA technology. Their genes are cloned, sequenced, and expressed in a host system, rather than being derived from immunized animals. This gives researchers precise control over the antibody's sequence, enabling consistent production, easy engineering, and reliable performance across experiments and manufacturing batches.
The process begins by identifying and cloning the genes encoding the antibody's variable regions. These genes are inserted into an expression vector, which is then introduced into a host cell, commonly CHO, HEK293, or E. coli. The host cells produce the antibody protein, which is then harvested and purified. Because the sequence is defined from the start, the antibody can be reproduced identically at any time.
Yes, and increasingly so. Recombinant antibodies are well-suited for flow cytometry because their consistent sequence and defined binding characteristics reduce lot-to-lot variability — a common frustration with hybridoma-derived antibodies. They can also be conjugated to fluorescent dyes or other labels with greater precision, making them reliable tools for immunophenotyping and cell sorting applications.
Recombinant antibodies are not inherently fluorescent, but they can be made so. One approach is chemical conjugation, attaching a fluorescent dye to the purified antibody. Another is genetic fusion, where a fluorescent protein such as GFP is encoded directly into the antibody construct. The latter approach, possible because the antibody sequence is fully known, is a distinct advantage of the recombinant format.
Start with the application, whether it's WB, IHC, ELISA, or flow cytometry, and confirm the antibody has been validated for it. Check the target specificity, host species, and whether the antibody has a defined, published sequence. Lot-to-lot consistency data and peer-reviewed citations are also worth reviewing. Suppliers such as AAA Biotech provide detailed validation data alongside their recombinant antibody catalog, which helps narrow the selection meaningfully.
Generally, yes; particularly in terms of reproducibility. Traditional monoclonal antibodies depend on living hybridoma cell lines, which can drift or be lost. Recombinant antibodies are defined by their DNA sequence, so the same antibody can be re-expressed at any point with identical performance. This makes them more reproducible across experiments, labs, and time, which is a meaningful advantage in research that demands consistency.
Like all antibodies, recombinant antibodies work by binding specifically to a target antigen through their variable regions. What distinguishes them is that this binding specificity is encoded in a known, stable DNA sequence. Once expressed, they function through the same antigen-antibody interaction that the recombinant format simply ensures the antibody's structure and behavior are more predictable and reproducible than conventionally produced counterparts.
Adoption has grown substantially over the past decade. Many journals and funding bodies now encourage or require the use of validated, sequence-defined antibodies to improve research reproducibility, and recombinant antibodies meet that standard. They are now common in academic research, diagnostics development, and drug discovery pipelines, with demand continuing to rise as researchers move away from poorly characterized polyclonal and hybridoma-derived antibodies.
In biopharmaceuticals, recombinant antibodies are not just popular; they are dominant. Nearly all approved therapeutic monoclonal antibodies are produced recombinantly. The format allows for precise engineering of effector function, half-life, immunogenicity, and manufacturability. From checkpoint inhibitors to antibody-drug conjugates, the biopharmaceutical industry has built its antibody pipeline almost entirely on recombinant technology.
Design begins with defining the target epitope and the intended application. Variable region sequences are selected, either from existing antibodies, phage display campaigns, or computational design. The sequences are then codon-optimized for the chosen expression host and cloned into an appropriate vector with the desired antibody format (IgG, Fab, scFv, etc.). Fc engineering can be incorporated at this stage to tune effector function or extend serum half-life.
Isolation typically involves screening a library: phage display, yeast display, or a hybridoma panel against the target antigen. Binders are identified through selection rounds, and individual clones are sequenced to confirm specificity. For phage or yeast display, iterative panning enriches for high-affinity binders. Once a sequence is confirmed, the antibody can be expressed recombinantly in a suitable host system for further characterization and scale-up.
The standard method for IgG-format recombinant antibodies is Protein A or Protein G affinity chromatography, which selectively captures antibodies from the conditioned media or cell lysate. This is followed by polishing steps, such as ion exchange or size exclusion chromatography, to remove aggregates and host cell impurities. Final formulation involves buffer exchange and filtration. The process is well-established and scalable, which is one practical benefit of working in the recombinant format.
In CHO cells, recombinant antibodies are expressed and secreted into the culture medium. The antibody genes, carried on an expression vector, are transcribed in the nucleus and translated in the cytoplasm. The nascent antibody chains enter the endoplasmic reticulum for folding and assembly, pass through the Golgi apparatus for glycosylation, and are then secreted extracellularly, where they can be harvested directly from the conditioned medium.
Contact us
Our expert team is here to help with your scientific queries and experiment needs via Chat, email, or phone. Let's make progress together.